Hypersensitivity to the CGRP Inhibitor Monoclonal Antibodies Galcanezumab, Erenumab, and Fremanezumab With Tolerance to Eptinezumab

J Investig Allergol Clin Immunol. 2024 Oct;34(5):348-349. doi: 10.18176/jiaci.1000.

Authors

B Barroso^{1

2}, J M Rodrigo-Muñoz^{2

3}, M Gil-Martínez^{2

3}, V Del Pozo^{2

3}, J Rodríguez-Vico⁴, D Betancor^{1

2}, M Valverde-Monge^{1

2}, A Gómez-López¹, J Sastre^{1

2}

Affiliations

¹ Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
² CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
³ Immunology Department, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain.
⁴ Headache Unit, Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

PMID: 39441051
DOI: 10.18176/jiaci.1000

No abstract available

Keywords: Eptinezumab; Erenumab; Fremanezumab; Galcanezumab; Hypersensitivity.